Health Care·Biotechnology·$2.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.81 | N/A | -7.71% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.81 | N/A | -7.71% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management acknowledged the difficulties faced in the current quarter. They remain focused on advancing their clinical programs despite the financial losses.
Management highlighted ongoing challenges in achieving profitability.
They emphasized the importance of upcoming clinical trials for future growth.
Celldex Therapeutics reported a wider-than-expected loss per share, which reflects ongoing challenges in their business. However, the stock rose by 3.23% after the earnings report, likely due to investor optimism about their future clinical trials. The lack of revenue data and guidance may leave some investors cautious about the company's near-term outlook.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
PALANTIR TECHNOLOGIE Class A
May 5, 2025